| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/10-1/50 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cytochrome P450 3A43, CYP3A43 |
| Entrez GeneID | 64816 |
| WB Predicted band size | 57.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CYP3A43 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 242-270 amino acids from the Central region of human CYP3A43. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于CYP3A43抗体的3篇参考文献，按研究内容简要总结如下：
---
1. **文献名称**：*"Discovery and characterization of the CYP3A43 gene: Antibody development and tissue expression analysis"*
**作者**：Gellner K, et al.
**摘要**：该研究首次报道了CYP3A43基因的发现，并开发了针对其编码蛋白的多克隆抗体。通过Western Blot和免疫组化验证抗体特异性，发现CYP3A43在肝脏和睾丸中低水平表达，提示其潜在代谢功能。
2. **文献名称**：*"Comparative expression profiling of CYP3A isoforms and antibody cross-reactivity studies"*
**作者**：Westlind-Johnsson A, et al.
**摘要**：研究比较了CYP3A家族成员(包括CYP3A43)的mRNA和蛋白表达水平。利用特异性抗体检测发现，CYP3A43蛋白在肝脏中表达极低，且与其他CYP3A成员(如CYP3A4/5)存在抗体交叉反应性挑战。
3. **文献名称**：*"CYP3A43 localization in extrahepatic tissues using immunohistochemistry: Implications for drug metabolism"*
**作者**：Koch I, et al.
**摘要**：通过定制多克隆抗体，研究揭示了CYP3A43在脑、前列腺等肝外组织的特异性定位，提示其可能参与局部药物或内源性物质代谢，并讨论了抗体在病理模型中的应用潜力。
---
**备注**：CYP3A43因表达量低且与CYP3A亚家族高度同源，相关抗体研究较少，上述文献侧重抗体开发及初步应用。如需实验级抗体验证建议，需结合最新研究或商业抗体数据。
The CYP3A43 antibody is a research tool targeting the CYP3A43 enzyme, a member of the cytochrome P450 3A subfamily involved in drug metabolism and xenobiotic detoxification. Unlike its well-studied isoforms (e.g., CYP3A4), CYP3A43 is poorly characterized due to its low expression levels and restricted tissue distribution, primarily observed in the liver, testes, and brain. Its functional role remains unclear, though genetic polymorphisms in CYP3A43 have been linked to altered drug responses and disease susceptibility, including prostate cancer.
Antibodies against CYP3A43 are essential for detecting and quantifying its protein expression, enabling studies on its regulation, interindividual variability, and potential clinical relevance. These antibodies (monoclonal or polyclonal) are typically validated for applications like Western blotting, immunohistochemistry, or immunofluorescence. However, challenges persist due to high sequence homology among CYP3A isoforms, necessitating rigorous specificity testing.
Research using CYP3A43 antibodies could clarify its contribution to drug-drug interactions, metabolic disorders, or cancer progression. Despite limited commercial availability, such tools are critical for exploring CYP3A43's unique physiological or pathological roles, particularly in personalized medicine contexts where genetic variations impact therapeutic outcomes. Ongoing studies aim to resolve its catalytic activities and tissue-specific functions, bridging gaps in understanding P450-mediated metabolic networks.
×
